Clinical Trial Update: PA21 Safety and Efficacy in Adult Chinese Subjects [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating PA21 safety and efficacy in adult Chinese subjects with chronic kidney disease on dialysis and hyperphosphatemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease On Dialysis
• Hyperphosphatemia

Drugs mentioned

• PA21 (PA21)

Snippet

Sponsor: Vifor Fresenius Medical Care Renal Pharma | Conditions: Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia | Phase 3 | Status: COMPLETED